Repeat infections with RSV are believed to be common ... from a targeted pathogen in a proprietary parainfluenza virus 5 vector. Clinical data have shown that administration of our intranasal ...
Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect ...
Respiratory syncytial virus (RSV) is a highly contagious and ... from a targeted pathogen in a proprietary parainfluenza virus 5 vector. Clinical data have shown that administration of our ...
Five years ago, on March 11, the World Health Organization declared COVID-19 a global pandemic. The vaccines “underwent the most intensive safety analysis in U.S. history." ...
Respiratory syncytial virus (RSV) is a highly contagious and common respiratory ... by expressing a protein from a targeted pathogen in a proprietary parainfluenza virus 5 vector. Clinical data have ...
Arrow Therapeutics focused exclusively on novel antiviral drug discovery and development, including several different approaches towards Hepatitis C and Respiratory Syncytial Virus (RSV).
Among older adults in Spain, hospitalization rates from respiratory syncytial virus (RSV) infection increases progressively ...
1d
News-Medical.Net on MSNRSV hospitalization rates rise with age and chronic conditions in older adultsAmong older adults in Spain, hospitalization rates from respiratory syncytial virus (RSV) infection increases progressively with age and is more likely among people with other health issues and who ...
10h
RSVP Live on MSNIrish doctor shares serious warning after surge in virus 'nastier than RSV' in childrenCork doctor Niamh Lynch has warned about a childhood virus doing the rounds 'hated more than RSV', warning that adenovirus ...
The man’s case didn’t give rise to any widespread variant, but it gave Gupta, with his HIV evolution background, the idea ...
Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. Earlier this month ...
There was no association observed between respiratory syncytial virus vaccination and increased risk for atrial fibrillation in older adults with preexisting conditions, supporting the use of RSV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results